Global Phage Therapy Market Projected to Reach USD 1.86 Billion by 2035 Driven by Rising Antibiotic Resistance – SNS Insider
Advances in precision medicine and bacteriophage engineering drive steady growth, despite regulatory and cost challenges.
Austin, United States, April 21, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, The Phage Therapy Market Size is valued at USD 1.27 Billion in 2025 and is projected to reach USD 1.86 Billion by 2035, growing at a CAGR of 3.91% during the forecast period 2026–2035. Phage engineering, the use of precision medicine, the rise in antibiotic resistance, and the expansion of clinical and non-human applications between 2026 and 2035 are the factors driving the market’s growth prospects.
Market Size and Forecast:
- Market Size (2025): USD 1.27 Billion
- Market Size (2035): USD 1.86 Billion
- CAGR (2026–2035): 3.91%
- Base Year: 2025
- Forecast Period: 2026–2035
- Historical Data: 2022–2024
Get a Sample Report of Phage Therapy Market: https://www.snsinsider.com/sample-request/9881
Rising Antibiotic Resistance and Demand for Targeted Therapeutics to Propel Market Growth Globally
The demand for focused therapy and antibiotic resistance, are two of the main reasons propelling the growth of the phage therapy market. As phage therapy is more accurate and efficient in treating bacterial illnesses, its use is growing. It works well against bacterial types that are resistant to conventional antibiotics. Hospitals, veterinary clinics, and farms are using phage therapy more frequently to control infections. The market is being driven by the need for research and knowledge of alternative antibiotics.
Major Phage Therapy Market Companies Listed in the Report are
- Adaptive Phage Therapeutics
- Armata Pharmaceuticals
- Locus Biosciences
- Intralytix, Inc.
- Pherecydes Pharma
- EnBiotix, Inc.
- Eligo Bioscience
- ContraFect Corporation
- Micreos B.V.
- Nextbiotics
- Phagomed Biopharma GmbH
- PhagePro, Inc.
- TechnoPhage
- Proteon Pharmaceuticals
- Eliava BioPreparations
- Fixed-Phage Ltd.
- BiomX Ltd.
- iNtODEWORLD
- Phagelux
- InnoPhage Ltd.
Segmentation Analysis:
By Phage / Product Type
dsDNA Bacteriophage held the largest market share of 38.45% in 2025 due to the high utilization of dsDNA bacteriophages for human therapeutics, veterinary and research purposes. Phage Cocktails / Engineered Preparations are expected to grow at the fastest CAGR of 5.42% during 2026–2035 due to increasing demand for multi-target phage therapies or precision-engineered solutions.
By Administration / Route
Injectable / Surgical Administration accounted for the highest market share of 41.32% in 2025 due to their administration directly at infection cite and elevated clinical efficiency particularly at hospitals and veterinary surgical theatres. Oral administration is projected to register the fastest CAGR of 5.08% through 2026–2035 due to patient willingness and ease of usability for them and their potential use in agriculture and aquaculture.
By Application / Use Case
Human Therapeutics dominated with a 42.56% market share in 2025 owing to the increasing case of antibiotic-resistant infections and growth in its clinical usage. Agriculture & Crop Protection is expected to grow at the fastest CAGR of 6.02% during the forecast period owing to the necessity for increased sustainable disease control and decreased use of chemical pesticides.
By End-User / Customer Type
Hospitals & Clinics captured the highest market share of 44.68% in 2025 due to early adoption of phage therapies, particularly in cases of antibiotic-resistant infections and complex clinical conditions. Agricultural Enterprises are anticipated to expand at the fastest CAGR of 5.97% through 2026–2035 owing to the need for environmental-friendly bacterial control of crops and livestock.
By Target Bacterial Indication / Disease
Urinary Tract Infections held the largest share of 36.84% in 2025 due to high prevalence rates and established success of phage therapies for the treatment of these resistant strains. Chronic Conditions are expected to grow at the fastest CAGR of 5.68% during the forecast period due to the growing clinical trials and enrichment of existing phage cocktails globally.
Do you have any specific queries or need any customization research on Phage Therapy Market, make an Enquiry Now: https://www.snsinsider.com/enquiry/9881
Phage Therapy Market Key Segments
By Phage / Product Type
- dsDNA Bacteriophage
- ssDNA Bacteriophage
- ssRNA Bacteriophage
- Phage Cocktails / Engineered Preparations
- Delivery / Formulation Types
By Administration / Route
- Oral
- Topical / External Application
- Injectable / Surgical Administration
By Application / Use Case
- Human Therapeutics
- Veterinary Medicine
- Agriculture & Crop Protection
- Aquaculture
- Food Safety & Preservation
- Research & Development / Diagnostics
By End-User / Customer Type
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Research & Academic Institutions
- Veterinary Care Providers
- Food & Beverage / Processing Industry
- Agricultural Enterprises
By Target Bacterial Indication / Disease
- Urinary Tract Infections
- Wound & Skin Infections
- Respiratory Infections
- Bone & Orthopedic Infections
- Chronic Conditions
- Other Pathogen-Specific Indications
Regional Insights:
The U.S. Phage Therapy Market is projected to grow from USD 0.44 Billion in 2025 to USD 0.60 Billion by 2035, at a CAGR of 2.99%. Growing antibiotic resistance, the clinical use of phage-based treatments, the complexity of biotech infrastructure in developed economies, significant investment in R&D, and regulatory frameworks that facilitate access to new treatments are the factors driving the market.
Due to the early acceptance of phage-based medicines and the increase in antibiotic resistance, the North American phage therapy market is dominating, with a 41.87% share in 2025. Around the world, more than 50,000 treatments were given in clinics, hospitals, and research facilities. Advanced biotechnology skills, significant R&D investments, and the existence of important phage therapy firms are further factors propelling the market.
Asia-Pacific is expected to develop at a compound annual growth rate (CAGR) of 5.29% between 2026 and 2035, making it the fastest-growing region in the phage therapy market. Growing antibiotic resistance, the use of phage therapies in the human, animal, and agricultural sectors, and government programs to advance biotechnology are all contributing factors to the market’s expansion.
Recent Developments:
- In December 2025, Adaptive Phage Therapeutics expanded its Series B funding, securing significant investment to accelerate clinical phage programs targeting antibiotic-resistant infections. This development strengthens its pipeline, enhances personalized phage therapy, and reinforces its leadership in adaptive phage solutions.
- In November 2025, Armata Pharmaceuticals commissioned a state-of-the-art cGMP phage manufacturing facility, enabling high-purity production of therapeutic phages. This development supports clinical trials, regulatory readiness, and reinforces the company’s leadership in pathogen-specific bacteriophage therapies.
Exclusive Sections of the Report (The USPs):
- ADVANCED R&D & BIOENGINEERING INNOVATION METRICS – helps you understand technological advancements through insights on CRISPR-engineered bacteriophages, synthetic biology applications, delivery systems, combination therapies, and formulation stability improvements.
- MARKET PENETRATION & COMMERCIALIZATION STRATEGY INSIGHTS – helps you evaluate growth potential through cost comparisons with antibiotics, regional adoption in AMR-affected markets, strategic partnerships, investment trends, and licensing opportunities.
- CLINICAL EFFICACY & PATIENT OUTCOME BENCHMARKS – helps you assess treatment effectiveness through clinical trial adoption, efficacy rates by bacterial strain, patient compliance, safety profiling, and expansion across human and veterinary applications.
- PRECISION MEDICINE & TARGETED THERAPY LANDSCAPE – helps you identify future opportunities through integration with diagnostics, development of personalized phage therapies, and differentiation between broad-host and narrow-host phage applications.
- COMPETITIVE STRATEGY & EMERGING APPLICATION INSIGHTS – helps you gauge industry dynamics through collaboration trends, innovation in targeted infection treatment, and expansion into niche areas such as chronic infections, AMR hotspots, and biofilm-related conditions.
Buy an Enterprise-User PDF of Phage Therapy Market Outlook Report 2026-2035: https://www.snsinsider.com/checkout/9881
Phage Therapy Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 1.27 Billion |
| Market Size by 2035 | USD 1.86 Billion |
| CAGR | CAGR of 3.91% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Related Market Reports
Antimicrobial Resistance Surveillance Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
